Vilitra: Expert-Grade Erectile Dysfunction Treatment for Reliable Performance
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $7.26 | $72.63 (0%) | 🛒 Add to cart |
| 20 | $4.94 | $145.26 $98.86 (32%) | 🛒 Add to cart |
| 30 | $4.17 | $217.89 $125.09 (43%) | 🛒 Add to cart |
| 40 | $3.76 | $290.52 $150.30 (48%) | 🛒 Add to cart |
| 60 | $3.38 | $435.78 $202.76 (53%) | 🛒 Add to cart |
| 90 | $3.14 | $653.67 $282.45 (57%) | 🛒 Add to cart |
| 120 | $3.00 | $871.56 $360.12 (59%) | 🛒 Add to cart |
| 180 | $2.87
Best per pill | $1307.34 $517.49 (60%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Vilitra, containing the active pharmaceutical ingredient Vardenafil, is a prescription medication specifically formulated for the treatment of erectile dysfunction (ED). As a potent phosphodiesterase type 5 (PDE5) inhibitor, it operates by enhancing blood flow to the penile tissues, facilitating the achievement and maintenance of an erection sufficient for satisfactory sexual activity. This medication is recognized for its rapid onset of action and sustained efficacy, making it a trusted choice among healthcare providers for managing this common condition. Proper diagnosis and adherence to medical guidance are imperative for safe and effective use.
Features
- Active Ingredient: Vardenafil Hydrochloride
- Available Strengths: 10 mg, 20 mg, 40 mg, and 60 mg film-coated tablets
- Mechanism of Action: Selective inhibition of phosphodiesterase type 5 (PDE5)
- Onset of Action: Typically within 25-60 minutes post-administration
- Duration of Effect: Efficacy can persist for up to 4-5 hours
- Administration: Oral, with or without food (though high-fat meals may delay absorption)
- Manufacturer: Centurion Laboratories, complying with international Good Manufacturing Practices (GMP)
Benefits
- Facilitates the achievement of firm and sustainable erections when sexually stimulated.
- Enhances overall sexual confidence and reduces performance-related anxiety.
- Offers a predictable and reliable therapeutic window for planned sexual activity.
- Improves relationship satisfaction by addressing a key physiological aspect of sexual health.
- Provides a well-tolerated treatment option with a established safety profile when used as directed.
- Allows for flexibility in timing due to its relatively rapid onset and extended duration.
Common use
Vilitra (Vardenafil) is primarily indicated for the management of erectile dysfunction in adult males. It is used to ameliorate the inability to attain or maintain a penile erection adequate for satisfactory sexual performance. It is not indicated for use in women, children, or adolescents. Its use is contingent upon sexual stimulation; it does not automatically induce an erection. It may be prescribed as part of a broader therapeutic approach to sexual health, which can include psychological counseling or management of underlying health conditions contributing to ED, such as diabetes or cardiovascular disease.
Dosage and direction
The recommended starting dose of Vilitra is 10 mg, taken orally approximately 25-60 minutes prior to anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 20 mg or decreased to 5 mg. The maximum recommended dosing frequency is once per day. The tablet should be swallowed whole with a glass of water; it should not be split, crushed, or chewed. For the 60 mg strength, specific medical supervision is advised. Dosing must be individualized by a healthcare professional considering the patient’s health status, concomitant medications, and therapeutic response. The use of Vilitra in combination with other treatments for erectile dysfunction is not recommended.
Precautions
Prior to initiating treatment with Vilitra, a thorough medical assessment is essential to diagnose the underlying cause of erectile dysfunction and to assess cardiovascular health, as sexual activity carries potential cardiac risk. Use with caution in patients with anatomical deformation of the penis, history of priapism, bleeding disorders, or active peptic ulceration. Caution is advised in patients with severe hepatic impairment (Child-Pugh class C), severe renal impairment (creatinine clearance <30 mL/min), or hypotension. Vilitra offers no protection against sexually transmitted diseases. Patients with cardiovascular conditions such as heart failure, coronary artery disease, or unstable angina should be evaluated for safety before engaging in sexual activity. Avoid excessive alcohol consumption, as it may increase the risk of orthostatic hypotension and diminish efficacy.
Contraindications
Vilitra is contraindicated in patients with a known hypersensitivity to Vardenafil or any of the tablet’s excipients. Its concurrent administration with any form of organic nitrates or nitric oxide donors (e.g., nitroglycerin, isosorbide mononitrate or dinitrate, amyl nitrite) is strictly contraindicated due to the risk of profound hypotension, syncope, myocardial infarction, or stroke. It is also contraindicated in patients using guanylate cyclase stimulators, such as riociguat. Concomitant use with potent CYP3A4 inhibitors like ketoconazole, itraconazole, ritonavir, or indinavir in patients for whom a reduced dose is not available is contraindicated. Use is not recommended in patients with severe hepatic impairment, severe hypotension (BP <90/50 mmHg), recent stroke or myocardial infarction, or unstable angina.
Possible side effects
Like all pharmaceuticals, Vilitra can cause side effects, although not everybody experiences them. Common side effects (≥1/100) include headache, flushing, nasal congestion, indigestion, and dizziness. Uncommon side effects (≥1/1,000 to <1/100) may include blurred vision, changes in color vision, photophobia, palpitations, tachycardia, hypotension, nausea, and back pain. Rare side effects (≥1/10,000 to <1/1,000) include priapism (a prolonged and painful erection lasting more than 4 hours), syncope, sudden hearing loss, and non-arteritic anterior ischemic optic neuropathy (NAION). Allergic reactions, including rash and itching, may occur. Patients experiencing an erection lasting more than 4 hours or a sudden loss of vision must seek immediate medical attention.
Drug interaction
Vilitra is primarily metabolized by the hepatic enzyme CYP3A4, with contributions from CYP3A5 and CYP2C isoforms. Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin) will significantly increase Vardenafil plasma concentrations; dose adjustment or avoidance is necessary. Concomitant administration with alpha-blockers (e.g., doxazosin, tamsulosin) can potentiate the blood-pressure-lowering effects and is not recommended. Caution is advised with other antihypertensive agents. Concurrent use with other PDE5 inhibitors is contraindicated. Grapefruit juice may increase plasma levels of Vardenafil and should be avoided. Alcohol can potentiate vasodilatory and hypotensive effects.
Missed dose
Vilitra is not intended for scheduled daily administration; it is taken on an as-needed basis prior to sexual activity. Therefore, the concept of a “missed dose” does not apply in the traditional sense. If a dose is not taken within the planned timeframe, it should simply be taken when needed for subsequent sexual activity, adhering to the maximum once-daily dosing frequency. Do not take a double dose to make up for a missed one.
Overdose
In cases of suspected overdose, standard supportive measures should be employed. Given its vasodilatory effects, the primary manifestation of a Vilitra overdose is likely to be severe hypotension. Cardiovascular monitoring is essential. Management of hypotension should include placing the patient in the Trendelenburg position and administering intravenous fluids. If necessary, vasopressor agents may be considered. Hemodialysis is not expected to significantly accelerate clearance, as Vardenafil is highly protein-bound and extensively metabolized.
Storage
Store Vilitra tablets below 30°C (86°F) in their original packaging to protect from light and moisture. Keep the container tightly closed. Keep out of the sight and reach of children. Do not use after the expiration date printed on the blister strip and carton. Do not dispose of medications via wastewater or household waste; consult your pharmacist for proper disposal methods to protect the environment.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the typical properties of the medication and may not be accurate for all individuals or specific situations.
Reviews
“After being diagnosed with ED related to my type 2 diabetes, my urologist prescribed Vilitra 20mg. The effect is consistent and reliable, typically within 40 minutes, and has significantly reduced the anxiety I associated with intimacy. I experienced mild flushing initially, but it subsided.” – Mark T., 54
“I found the 10mg dose to be effective with minimal side effects—just a slight stuffy nose. It’s given me back a sense of normalcy in my relationship. I appreciate that my doctor took the time to explain how it works and the importance of not using it with my heart medication.” – David R., 61
“As a healthcare professional, I value evidence-based treatments. Vilitra’s pharmacokinetic profile makes it a practical option for many of my patients. It’s important to manage expectations; it is an effective tool but requires appropriate stimulation and is not an aphrodisiac.” – Dr. Evans, Urologist